PLEASANTON, Calif.--(BUSINESS WIRE)--NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced activities planned for the 112th American Urological Association Annual Meeting taking place May 12-16 at the Boston Convention and Exhibition Center in Boston, Mass.
The company’s events and activities will highlight the UroLift® System, a revolutionary minimally invasive approach to treating benign prostatic hyperplasia (BPH), also called enlarged prostate. These presentations include:
- Friday, May 12, 7:00 am ET in Room 156, poster presentation by Dr. Karl-Dietrich Sievert: Minimally Invasive Prostatic Urethral Lift (PUL) Efficacious in a Large Percentage of TURP Candidates: A Multi-Center German Study After Two Years
- Saturday, May 13, 7:00am-9am ET in Room 252: presentations of results from the Crossover Study (Prof. Henry Woo); the LOCAL Study (Dr. Steven Gange); and Commercial Use (Dr. Andrew Hirsh)
- Saturday, May 13, at 1:00pm ET in Room 162: Five-year results from the pivotal L.I.F.T. randomized study presented by Dr. Claus Roehrborn as part of a podium session titled BPH: Surgical Therapy & New Technology IV
- Sunday, May 14, 9:30-10:30am ET, in the Plenary Room: A presentation of Prime Time Surgical Techniques featuring the UroLift System, including a presentation and case demonstration of the UroLift System by Dr. Shahin Tabatabei
In addition, presentations will take place in Booth 620 each day beginning at 10am every hour, on the hour.
About the UroLift System
The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.